Anika Therapeutics (ANIK) Tops Q4 EPS by 21c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/7/2026
- S&P 500, Nasdaq close sharply higher as Broadcom rallies
- Oil prices settle at pre-Iran war levels as crude output grows
- Broadcom stock pops 4% as Apple silicon deal gets extended through 2031
- Buy the pullback in chip stocks, JPM's Matejka says
- Memory stocks rebound as analysts flag a buying opportunity
- Rivian Automotive (RIVN) files for 75M share offering
- Rivian offers Q2 2026 revenue outlook, cash position grows
- Nokia OYJ (NOKIA:FH) (NOK) PT Raised to EUR14 at Kepler Cheuvreux
- Meta capex to surge in 2027, neocloud fears ’erroneous’ - SemiAnalysis
- S&P 500, Nasdaq close sharply higher as Broadcom rallies
Sidoti Downgrades Anika Therapeutics (ANIK) to Neutral
February 22, 2019 8:48 AM ESTSidoti analyst James Sidoti downgraded Anika Therapeutics (NASDAQ: ANIK) from Buy to Neutral with a price target of $41.00 (from $56.00).
The analyst cited uncertainty regarding CINGAL approval.
For an analyst ratings summary and ratings history on Anika Therapeutics... More
